Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02282371

Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC)

Head and Neck Squamous Cell Cancer Clinical Trial

Official title:
A Phase Ib Study of Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC)

Clinical Trial Summary

This is a phase 1b study, which means that the purpose of the study is to establish the maximum dose of a pill drug called BYL719, when given with a standard treatment for patients with head and neck squamous cell cancer.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02282371
Study type Interventional
Source Memorial Sloan Kettering Cancer Center
Contact
Status Completed
Phase Phase 1
Start date October 30, 2014
Completion date October 22, 2021
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03667482 - Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer Phase 1
Completed NCT02083692 - Pilot Study of Metformin in Head and Neck Squamous Cell Cancer and Its Effects on Stromal-epithelial Metabolic Uncoupling Early Phase 1
Active, not recruiting NCT03138070 - A Window of Opportunity Study to Assess the Modulation of Biomarkers in Head and Neck Squamous Cell Cancer (HNSCC) By Preoperative Treatment With BYL719 N/A
Active, not recruiting NCT02159508 - Intensive Nutrition Counselling in Patients With Head and Neck Cancer N/A
Completed NCT02252042 - Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040) Phase 3
Terminated NCT01790516 - Use of Pharmacogenetics to Select Erbitux or Cisplatin to Treat Head and Neck Cancer N/A
Completed NCT00574977 - Safety Study of Modified Vaccinia Virus to Cancer Phase 1
Completed NCT00592371 - Head and Neck Cancer Screening and Serum Repository N/A
Recruiting NCT02485548 - Cisplatin Plus Raltitrexed or 5-fluorouracil Concurrent With Radiotherapy for Head and Neck Squamous Cell Cancer Phase 3
Terminated NCT01326923 - Induction Chemo Then Concurrent Chemoradiotherapy With Cetuximab in Locally Advanced Head and Neck Squamous Cell Cancer Phase 2
Not yet recruiting NCT03975270 - Sintilimab in Combination With Nab-paclitaxel in Patients With HNSCC (Head and Neck Squamous Cell Carcinoma ) Phase 2
Terminated NCT04187872 - LITT and Pembrolizumab in Recurrent Brain Metastasis Phase 1
Recruiting NCT02327468 - Inovio TRT-001: Telomerase DNA Immunotherapy in Breast, Lung, and Pancreatic Cancers Phase 1
Active, not recruiting NCT01351103 - A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands Phase 1
Terminated NCT00260598 - LIFE-Lung Bronchoscopy in Patients at Risk for Developing Lung Cancer Phase 2
Completed NCT02163057 - Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma Phase 1/Phase 2
Recruiting NCT04856631 - A Study of Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell Cancer Phase 1/Phase 2